Infinity Pharmaceuticals, Inc. announced that Lawrence Bloch has been promoted to president. In his new role, Dr. Bloch will retain responsibility for the finance, business development, corporate communications and investor relations functions at Infinity and will assume responsibility for pharmaceutical development as well as facilities operations. Dr. Bloch will continue to report to Adelene Perkins, Infinity's chief executive officer. Dr. Bloch joined Infinity as chief financial officer and chief business officer in 2012 and has played a key role in developing and executing the company's corporate and financial strategies. Additionally, the company has promoted Claudio Dansky Ullmann, M.D., to senior vice president, clinical development. Dr. Dansky Ullmann joined Infinity as vice president, clinical development in 2015 and has since led Infinity's clinical development team. Dr. Dansky Ullmann will join the executive leadership team and report to Ms. Perkins. Infinity also announced that Julian Adams president of research and development (R&D), will retire from the company effective January 6, 2017. Dr. Adams has been president of research and development at Infinity since 2003. Infinity also announced the promotion of Joseph Pearlberg, M.D to vice president, clinical development, and Melissa Hackel to vice president, finance. Dr. Dansky Ullmann has nearly 30 years of experience in drug development. Prior to joining Infinity, he served as a senior medical director, global clinical lead, at Takeda Pharmaceutical Company Limited from 2012 to 2015. From 2005 to 2012, Dr. Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute as a senior investigator where he participated in numerous early-phase and late-phase clinical trials, including studies evaluating treatments for lung and head and neck cancers, melanoma and other solid tumors. Dr. Joseph Pearlberg joined Infinity in 2014 and has 25 years of experience in research and medicine. Prior to joining Infinity, Dr. Pearlberg worked at Sanofi from 2010 to 2014 where he held various roles of increasing responsibility within the clinical development organization. Prior to that, Dr. Pearlberg held a postdoctoral fellowship at Harvard Medical School from 2002 to 2010. Melissa Hackel joined Infinity in 2015 and has more than 15 years of financial experience in the pharmaceutical and medical device industry and has made financial and operational contributions throughout her career leading and developing teams to manage financial analysis in support of strategic decision-making. Prior to joining Infinity, Ms. Hackel served as director of finance at Takeda Pharmaceutical Company.